Compare AU
Compare ROBO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Robo Global Robotics & Automation ETF (ROBO) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ROBO | CURE | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 549 | 85 |
Median incremental investment | $639.52 | $616.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,025.22 | $1,410.92 |
Average age group | 26 - 35 | > 35 |
Key Summary
ROBO | CURE | |
---|---|---|
Strategy | ROBO.AX was created on 2017-09-13 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the ROBO.AX Global Robotics and Automation Index (the Index) | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Symbotic Inc Ordinary Shares - Class A (2.15 %) Celestica Inc Ordinary Shares (Subordinate Voting) (1.93 %) NVIDIA Corp (1.91 %) | Viking Therapeutics Inc (3.00 %) Gilead Sciences Inc (2.76 %) Alnylam Pharmaceuticals Inc (2.76 %) |
Top 3 industries | Information Technology (40.93 %) Industrials (39.97 %) Health Care (19.10 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (80.07 %) Canada (19.93 %) | United States (100.00 %) |
Management fee | 0.82 % | 0.45 % |
Key Summary
ROBO | CURE | |
---|---|---|
Issuer | Global X | Global X |
Tracking index | ROBO Global Robotics and Automation TR Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.82 % | 0.45 % |
Price | $73.64 | $50.39 |
Size | $221.309 million | $39.185 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.87 % | 4.24 % |
Market | ASX | ASX |
First listed date | 14/09/2017 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ROBO | CURE | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 549 | 85 |
Median incremental investment | $639.52 | $616.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,025.22 | $1,410.92 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
ROBO | CURE | |
---|---|---|
Pros |
|
|
Cons |
|
|
ROBO | CURE |
---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |